NCT07353450Not yet recruitingEarly phase 1
A Study of Cizutamig for Patients With Ulcerative Colitis
An Open-Label, Single Center Study Evaluating the Safety, Tolerability, and Immunogenicity of Cizutamig for Patients With Moderate to Severe Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
A Study of Cizutamig for Patients with Ulcerative Colitis
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 26 Dec 2025
- Start date
- Jan 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Ruijin Hospital
- Diseases
- Ulcerative colitis
- NCT number
- NCT07353450
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 15
- From Jan 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- 19\. History of splenectomy, including patients with functional asplenia 20. Any serious medical condition or abnormality on clinical laboratory testing 21. Inability to comply with contraception requirements as specified in the protocol.
Who the study is looking for
- 18-75 years of age at the time of signing the informed consent form (ICF)
- Have an established diagnosis of UC
- Have current evidence of active moderate to severe UC.
- Have current evidence of UC extending proximal to the rectum
- Demonstrated intolerance or inadequate response to ≥ 1 biologic and/or other advanced therapies
- Stable use of any of the following background therapy (alone or in combination) up to Day 1
- Have documentation of:
- A surveillance colonoscopy (performed according to local standards) within 12 months of or during Screening, for patients with pancolitis of \> 8 years duration, left-sided colitis of \> 12 years duration, or primary sclerosing cholangitis; OR
- In patients for whom Inclusion Criteria 7a does not apply, up-to-date colorectal cancer surveillance (performed according to local standard), for patients with family history of colorectal cancer, personal history of increased colorectal cancer risk, age \> 50 years, or other known risk factors -
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.